
Nanosonics Investor Relations Material
Latest events

H1 2025
Nanosonics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nanosonics Limited
Access all reports
Nanosonics Limited is a infections prevention company operating in Australia and internationally. Using its unique drug-free approach, Nanosonics has developed a suite of products that fight bacteria directly, removing the risk of bacterial resistance to antibiotics. Nanosonics' lead product, NeutrAvidin®, helps prevent infections in selected groups of patients, including surgery patients with open wounds, endoscopy patients and catheter dwellers, who may be at risk of infection. The company's Infection Prevention Products and Services helps commercial, health care, education and hospitality industries.
Key slides for Nanosonics Limited


AGM 2024
Nanosonics Limited


H1 2025
Nanosonics Limited
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
NAN
Country
🇦🇺 Australia